Why Precision BioSciences, Inc.’s (DTIL) Stock Is Down 6.28%
As of Wednesday, July 29, Precision BioSciences, Inc.’s DTIL share price has dipped by 6.28%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Commentary & Analysis
Why Precision BioSciences, Inc.’s (DTIL) Stock Is Down 5.16%
As of Thursday, July 16, Precision BioSciences, Inc.’s DTIL share price has dipped by 5.16%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Precision BioSciences, Inc.’s (DTIL) Stock Is Down 6.28%
As of Friday, July 10, Precision BioSciences, Inc.’s DTIL share price has dipped by 6.28%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Precision BioSciences, Inc.’s (DTIL) Stock Is Up 7.77%
As of Tuesday, July 07, Precision BioSciences, Inc.’s DTIL share price has surged by 7.77%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Precision BioSciences, Inc.’s (DTIL) Stock Is Up 12.62%
As of Tuesday, July 07, Precision BioSciences, Inc.’s DTIL share price has surged by 12.62%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | DTIL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $180.4 | $252.6 | 27% |
|
| Shares Out (Mil) | 24.6 | 52.3 | 34% |
|
| Institutional Ownership | 92.4% | 92.1% | 61% |
|
| Float (Mil) | 22.0 | 40.2 | 31% |
|
| Beta | 1.31 | 0.95 | 76% |
|
| Avg Daily Volume (000s) | 259 | 455 | 48% |
|
| Price Change (52-week) |
45.6% | 52.9% | 78% |
|
| Growth | DTIL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 7.1% | 13.6% | 46% |
|
| Net Income (5yr) | 16.0% | (9.9%) | 65% |
|
| EPS (5yr) | 43.7% | 16.0% | 90 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 15.4% | (15.6%) | 74% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.670) | ($2.487) | ($1.893) | |
| Month Ago EPS | ($0.670) | ($2.487) | ($1.893) | |
| # Rev Up | 0 | 2 | 2 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.800) | ($3.160) | ($3.270) | |
| Year/Year Chg | (10.7%) | (31.6%) | (47.6%) | |
| Financials | DTIL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $45 | $38 | 19% |
|
| Net Income (TTM) (Mil) | ($44) | ($43) | 17% |
|
| EPS (TTM) | ($2.617) | ($1.600) | 12% |
|
| Operating Cash Flow (TTM) (Mil) | ($59) | ($31) | 8% |
|
| Net Cash Flow (TTM) (Mil) | $26 | $5 | 65% |
|
| Long-Term Debt (Q1) (Mil) | $27 | $5 | 34% |
|
| Enterprise Value (Q1) (Mil) | $112 | $180 | 22% |
|
| Valuation | DTIL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.37 | 2.56 | 57% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | DTIL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 63.8% | 96% |
|
| Net Margin | (96.7%) | (67.3%) | 8% |
|
| ROA | (32.5%) | (49.8%) | 16% |
|
| ROE | (69.5%) | (55.5%) | 12% |
|
| Liabilities to Assets | 47.1% | 30.3% | 38% |
|
| F-Score | 3 | 3 | 19% |
|
Precision BioSciences, Inc. did not pass any screens on 7/31/2026.
